I. Walters

1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile.

J. Unitt, H. Hunt, J. Belanoff, 2015, Bioorganic & medicinal chemistry letters.

Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.

J. Unitt, Bryan E. Roberts, A. Baxter, 2017, ACS medicinal chemistry letters.

Evaluation of a series of bicyclic CXCR2 antagonists.

R. Austin, R. Jewell, M. Christie, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of substrate-mimicking cytosolic phospholipase A2 inhibitors--reducing the lipophilicity of the arachidonyl chain isostere.

D. Murray, S. Connolly, I. Walters, 2004, Bioorganic & medicinal chemistry letters.

Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.

J. Unitt, H. Hunt, J. Belanoff, 2017, Journal of medicinal chemistry.

Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton.

D. Murray, S. Connolly, I. Walters, 2002, Journal of medicinal chemistry.

From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y2 receptor.

Michael J. Stocks, N. Kindon, I. Dougall, 2017, Bioorganic & medicinal chemistry letters.

Solid-Phase Synthesis of Tyrosine Peptide Aldehydes. Analogues of (S)-MAPI.

S. Teague, M. Bradley, I. Walters, 1999, The Journal of organic chemistry.